TuHURA Biosciences, Inc.
HURANasdaqCIK 1498382HealthcareFiscal year ends Dec 31
Reports and events: 346 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-11-0617:00 ET | 8-K | 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-452007 |
| 2026-10-1617:00 ET | 8-K | 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-424228 |
| 2026-09-2417:00 ET | 8-K | 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-401140 |
| 2026-09-1717:00 ET | 8-K | 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-394473 |
| 2026-09-1709:00 ET | 8-K/A | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-393847 |
| 2026-09-1617:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-393206 |
| 2026-09-0417:00 ET | 8-K | 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-383797 |
| 2026-08-2818:01 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000897069-26-001732 |
| 2026-08-2117:00 ET | 8-K | 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-361272 |
| 2026-08-1917:00 ET | 8-K | 3.02 Unregistered sale of equity; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-357087 |
| 2026-08-1408:00 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-350451 |
| 2026-08-1407:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-350425 |
| 2026-08-1317:00 ET | 8-K | 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-349540 |
| 2026-07-2917:00 ET | 8-K | 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-324174 |
| 2026-07-0916:05 ET | DEF 14A | Proxy statementPeriod 2026-08-18 | 0001193125-26-299680 |
| 2026-07-0717:30 ET | 8-K | 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-297668 |
| 2026-06-1716:30 ET | 8-K | 5.08 Item not in the standard list | 0001193125-26-274225 |
| 2026-05-2917:00 ET | 8-K | 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-248640 |
| 2026-05-1517:20 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-227245 |
| 2026-05-1517:10 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-227204 |
| 2026-04-3016:45 ET | 8-K/A | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-197609 |
| 2026-04-3016:30 ET | 10-K/A | Annual report, amendedPeriod 2025-12-31 | 0001193125-26-197486 |
| 2026-04-2207:40 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-168395 |
| 2026-04-0816:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-147660 |
| 2026-04-0108:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-135766 |
| 2026-03-3117:15 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-134950 |
| 2026-01-3016:00 ET | 8-K | 3.01 Delisting notice | 0001193125-26-031742 |
| 2025-12-1016:30 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-314302 |
| 2025-12-0517:00 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-25-309853 |
| 2025-11-2508:01 ET | 8-K | 7.01 Regulation FD disclosure | 0001193125-25-294581 |
| 2025-11-1817:03 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-286419 |
| 2025-11-1407:20 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-281539 |
| 2025-11-1407:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-281522 |
| 2025-11-0407:00 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-25-263523 |
| 2025-11-0316:10 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-262562 |
| 2025-10-3117:00 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-25-260924 |
| 2025-09-1816:07 ET | S-1/A | Registration statement, amended | 0001193125-25-207395 |
| 2025-09-1116:30 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-25-114235 |
| 2025-08-1416:31 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-108972 |
| 2025-08-1416:20 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-108909 |
| 2025-08-1216:30 ET | S-1 | Registration statement | 0001193125-25-179009 |
| 2025-08-1216:24 ET | 8-K/A | 9.01 Financial statements and exhibits | 0001193125-25-178993 |
| 2025-06-3017:00 ET | 8-K | 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-091693 |
| 2025-06-2718:00 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0000950170-25-090522 |
| 2025-06-2417:57 ET | 8-K | 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-089118 |
| 2025-06-1207:00 ET | 8-K | 9.01 Financial statements and exhibits | 0000950170-25-085116 |
| 2025-06-0616:42 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-137135 |
| 2025-05-1516:31 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-072745 |
| 2025-05-1516:20 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-072685 |
| 2025-05-0717:00 ET | 8-K/A | 5.02 Departure or appointment of officers or directors | 0000950170-25-065860 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 6, 2026, 18:07 ET. Listed shows no prices and gives no investment advice.